Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer

被引：0

作者：

Modi, Shanu

Pusztai, Lajos

Forero, Andres

Mita, Monica

Miller, Kathy D.

Weise, Amy

Krop, Ian

Burris, Howard, III

Kalinsky, Kevin

Tsai, Michaela

Liu, Minetta C.

Hurvitz, Sara A.

Wilks, Sharon

Ademuyiwa, Foluso

Diab, Sami

Han, Hyo S.

Kato, Giraldo

Nanda, Rita

O'Shaughnessy, Joyce

Kostic, Ana

Li, Martha

Specht, Jennifer

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA

[3] Univ Alabama Birmingham, Birmingham, AL USA

[4] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[5] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA

[6] Karmanos Canc Inst, Detroit, MI USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[9] Columbia Univ, Med Ctr, New York, NY USA

[10] Allina Hlth, Virginia Piper Canc Inst, Minneapolis, MN USA

[11] Mayo Clin, Rochester, MN USA

[12] Univ Calif Los Angeles, Los Angeles, CA USA

[13] Texas Oncol, San Antonio, TX USA

[14] Washington Univ, St Louis, MO USA

[15] US Oncol Denver, Denver, CO USA

[16] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[17] Virginia G Piper Canc Care Network, Scottsdale, AZ USA

[18] Univ Chicago, Chicago, IL 60637 USA

[19] Baylor Univ, Med Ctr, Waco, TX 76798 USA

[20] US Oncol, Texas Oncol, Dallas, TX USA

[21] Seattle Genet Inc, Bothell, WA USA

[22] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD3-14

引用

页数：1

共 50 条

[41] Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer
Hu, Xichun
Zhang, Jian
Xu, Binghe
Jiang, Zefei
Ragaz, Joseph
Tong, Zhongsheng
Zhang, Qingyuan
Wang, Xiaojia
Feng, Jifeng
Pang, Danmei
Fan, Minhao
Li, Jin
Wang, Biyun
Wang, Zhonghua
Zhang, Qunling
Sun, Si
Liao, Chunmei
INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (08) : 1961 - 1969
[42] Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Tolaney, Sara M.
Ziehr, David R.
Guo, Hao
Ng, Mei R.
Barry, William T.
Higgins, Michaela J.
Isakoff, Steven J.
Brock, Jane E.
Ivanova, Elena V.
Paweletz, Cloud P.
Demeo, Michelle K.
Ramaiya, Nikhil H.
Overmoyer, Beth A.
Jain, Rakesh K.
Winer, Eric P.
Duda, Dan G.
ONCOLOGIST, 2017, 22 (01): : 25 - 32
[43] Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Tolaney, Sara M.
Kalinsky, Kevin
Kaklamani, Virginia G.
D'Adamo, David R.
Aktan, Gursel
Tsai, Michaela L.
O'Regan, Ruth M.
Kaufman, Peter A.
Wilks, Sharon T.
Andreopoulou, Eleni
Patt, Debra A.
Yuan, Yuan
Wang, Grace
Savulsky, Claudio
Xing, Dongyuan
Kleynerman, Ella
Karantza, Vassiliki
Diab, Sami
CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3061 - 3068
[44] METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC).
Yardley, Denise A.
Melisko, Michelle E.
Forero, Andres
Daniel, Brooke R.
Montero, Alberto J.
Guthrie, Troy H.
Canfield, Vikki A.
Oakman, Catherine Angela
Chew, Helen K.
Ferrario, Cristiano
Volas-Redd, Gena H.
Young, Robyn R.
Henry, Norah Lynn
Aneiro, Lynn
He, Yi
Turner, Christopher D.
Davis, Thomas A.
Vahdat, Linda T.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[45] Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review
Jiang, Kuikui
Wang, Shusen
TRANSLATIONAL BREAST CANCER RESEARCH, 2025, 6
[46] Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
Jieqiong Liu
Ying Wang
Zhenluan Tian
Ying Lin
Hengyu Li
Zhaowen Zhu
Qiang Liu
Shicheng Su
Yinduo Zeng
Weijuan Jia
Yaping Yang
Shengqiang Xu
Herui Yao
Wen Jiang
Erwei Song
Nature Communications, 13
[47] Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
Liu, Jieqiong
Wang, Ying
Tian, Zhenluan
Lin, Ying
Li, Hengyu
Zhu, Zhaowen
Liu, Qiang
Su, Shicheng
Zeng, Yinduo
Jia, Weijuan
Yang, Yaping
Xu, Shengqiang
Yao, Herui
Jiang, Wen
Song, Erwei
NATURE COMMUNICATIONS, 2022, 13 (01)
[48] Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer
Zhou, Dan-Dan
Bai, Wei-Qi
Zhai, Xiao-Tian
Sun, Li-Ping
Zhen, Yong-Su
Li, Zhuo-Rong
Miao, Qing-Fang
MILITARY MEDICAL RESEARCH, 2021, 8 (01)
[49] Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates
Dalenc, Florence
Sarradin, Victor
Nicolai, Vincent
Franchet, Camille
Ung, Mony
BULLETIN DU CANCER, 2021, 108 (01) : 67 - 79
[50] Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial
Loap, Pierre
Loirat, Delphine
Berger, Frederique
Rodrigues, Manuel
Bazire, Louis
Pierga, Jean-Yves
Vincent-Salomon, Anne
Laki, Fatima
Boudali, Latifa
Raizonville, Laurence
Mosseri, Veronique
Jochem, Anne
Eeckhoutte, Alexandre
Diallo, Mamadou
Stern, Marc-Henri
Fourquet, Alain
Kirova, Youlia
JAMA ONCOLOGY, 2022, 8 (12) : 1802 - 1808

← 1 2 3 4 5 →